Iwa Kong

Iwa Kong

Auto-generated profile, based on publicly available information

Iwa Kong

Radiation Oncology, Juravinski Cancer Centre-McMaster University, Hamilton, CAN

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Brachytherapy
Verified
Journal Article
Closed access
IKIwa Kong
Iwa Kong
SVSachi Vorunganti
Sachi Vorunganti
MPMalti Patel
Malti Patel
TFThomas Farrell
Thomas Farrell
ETEmilia Timotin
Emilia Timotin
RHRobert Hunter
Robert Hunter

29 September 2018 in Cureus
Verified
Journal Article
Open access
PDF file
EDElysia Donovan
Elysia Donovan
CRClare J. Reade
Clare J. Reade
LELua R. Eiriksson
Lua R. Eiriksson
GPGreg Pond
Greg Pond
NANikita Arora
Nikita Arora
IKIwa Kong
Iwa Kong
Purpose: Serous adenocarcinoma is a rare, aggressive histologic subtype of endometrial cancer with a high rate of recurrence and a poor prognosis. The optimal adjuvant treatment for early-stage patients is unclear. Our objective was to evaluate the outcomes of stage IA serous endometrial cancers only treated at a single institution and determine whether our current approach of chemotherapy plus vaginal brachytherapy (VBT) is sufficient. Methods: A retrospective chart review of our institution's pathology database, including all cases of stage IA serous endometrial carcinoma from 2000-2014 was completed. Kaplan-Meier estimates were calculated for Overall and Recurrence-Free Survival (OS and RFS); hazard ratios were calculated using Cox proportional hazards modeling for independent prognostic factors. Results: There were 63 patients with stage IA serous endometrial cancer of whom 79.4% were surgically staged. Percent RFS was 76.5% at five years while OS was 84.7% for the whole cohort. One of the 23 patients receiving VBT and chemotherapy recurred at the vagina versus four of 32 patients who were observed. Two patients in the observation group recurred in the pelvis while there were no first pelvic recurrences in the VBT and chemotherapy group (non- significant). Overall survival was 95% in the brachytherapy and chemotherapy group versus 79.6% in the observation group (non-significant). Post-operative management included observation (n=33), combination VBT and chemotherapy (n=21), or chemotherapy with or without external beam radiation therapy (EBRT) (n=9). Discussion: We report one of the largest cohorts of serous endometrial cancer stage IA patients. Our results emphasize the inferior RFS and OS of stage IA serous versus endometrioid endometrial cancer patients. While some centers continue to use EBRT for these patients, our results demonstrate low pelvic recurrence rates with radiotherapy limited to VBT, as well as the high systemic risk regardless of treatment. We advocate for combination chemotherapy and brachytherapy given the poor outcomes in these patients.

1 July 2018 in Brachytherapy
Verified
Journal Article
Closed access
NSNegin Shahid
Negin Shahid
TCTimothy Craig
Timothy Craig
MWMary Westerland
Mary Westerland
AAAllison Ashworth
Allison Ashworth
MAMichelle Ang
Michelle Ang
IKIwa Kong
Iwa Kong

1 March 2015 in Journal of Medical Imaging and Radiation Sciences
Verified
Journal Article
Closed access
ETEmilia Timotin
Emilia Timotin
SVSachi Voruganti
Sachi Voruganti
MPMalti Patel
Malti Patel
IKIwa Kong
Iwa Kong

1 September 2016 in Radiotherapy and Oncology
Verified
Journal Article
Open access
PDF file
NSNegin Shahid
Negin Shahid
TCTimothy Craig
Timothy Craig
MWMary Westerland
Mary Westerland
AAAllison Ashworth
Allison Ashworth
MAMichelle Ang
Michelle Ang
IKIwa Kong
Iwa Kong

1 September 2016 in Radiotherapy and Oncology
Verified
Journal Article
Open access
PDF file
EDElysia Donovan
Elysia Donovan
LELua Eiriksson
Lua Eiriksson
CRClare Reade
Clare Reade
HKHarkiran Kaur
Harkiran Kaur
GPGregory Pond
Gregory Pond
IKIwa Kong
Iwa Kong